30 min Presentation:

Engineering T-cell engagers with complete killing selectivity through the closed-loop integration of ML and high-throughput experimentation

Track: Optimising Expression Platforms

Time: Wednesday, November 6^th, 2024, 12.15

Bio: James is the CEO of LabGenius, a next-generation antibody discovery company. LabGenius has pioneered the development of an ML-driven antibody engineering platform that’s capable of designing, conducting and, critically, learning from its own experiments. As CEO, James has raised >$70M in financing from top-tier VCs (e.g. M Ventures, Octopus Ventures, Lux Capital, Obvious Ventures, Atomico and Kindred) and struck R&D deals with top pharma companies like Sanofi. Prior to founding LabGenius, James completed a PhD at Imperial College where he developed novel methods for re-engineering protein nanocages for targeted drug delivery.

Abstract: T-cell engagers (TCEs) promise breakthroughs in the treatment of solid tumours but their progression in the clinic has been limited by on-target, off-tumour toxicity. In this talk, we describe how LabGenius’ platform combines high-throughput cell-based functional assays with ML to identify highly potent TCEs with switch-like killing selectivity for tumour cells. We also highlight how GenScript has supported LabGenius’ lead discovery process via the expression of mono-VHH parts that feed into the company’s lead optimisation platform.

30 min Presentation:

Seamless Concept to Candidate:  GenScript’s cutting-edge Technologies for Bispecific Development

Track: Engineering the Next Generation of Bispecific Antibodies

Time: Thursday, November 7^th, 9:30

Bio: Amanda joined GenScript in 2021 and is the senior marketing manager for GenScript's antibody drug discovery portfolio. Her previous work experience includes immunopathology research of animal diseases, immunoassay development for research and commercialized use, immunoassay manufacturing and licensure, and product management of automation technology and diagnostics. In her current role, Amanda oversees portfolio education, marketing campaign management, and provides sales and distribution support. Amanda has two Bachelor of Science degrees, in Microbiology and Biochemistry, and a Professional Science Masters (PSM) from Washington State University.

Abstract: Bispecific antibody drug development is a complex process requiring careful consideration of target biology, mechanism of action, antibody format, and other critical factors. Leveraging advanced technologies and strategic planning can help navigate these challenges and lead to successful therapeutic outcomes. Join Amanda as she discusses GenScript’s integrated technologies that will support your bispecific design, expression, and assess your developability.

Leveraging GenScript’ s DNA mutant Libraries for AI-based epitope-specific antibody Drug Design

POSTER SESSION B: Wednesday 6 November C7B: Machine Learning Approaches for Protein Engineering: Part 1

Poster B038

Abstract: Discovering antibodies based on specific antigen-epitopes is one of the important sources for differentiating antibody-drugs especially when homogenization of drug targets is quite prevalent in current. Targeting specific epitopes have potence to generate antibody drugs with better efficacy and higher safety. Learn about how Genscript synthetic DNA mutant Libraries realize artificial intelligence and machine learning (AI/ML) design to facilitate epitope-specific antibody drug development.